<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAAD Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">JAAD Case Rep</journal-id><journal-title-group><journal-title>JAAD Case Reports</journal-title></journal-title-group><issn pub-type="epub">2352-5126</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38125968</article-id><article-id pub-id-type="pmc">PMC10731593</article-id><article-id pub-id-type="pii">S2352-5126(23)00416-2</article-id><article-id pub-id-type="doi">10.1016/j.jdcr.2023.11.001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Series</subject></subj-group></article-categories><title-group><article-title>Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Katamanin</surname><given-names>Olivia</given-names></name><degrees>BS</degrees><email>olivia.katamanin@my.rfums.org</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Ch&#x02019;en</surname><given-names>Peter Yi</given-names></name><degrees>BS</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Song</surname><given-names>Eingun James</given-names></name><degrees>MD</degrees><email>esong812@gmail.com</email><xref rid="aff3" ref-type="aff">c</xref><xref rid="cor2" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1"><label>a</label>Chicago Medical School, Rosalind Franklin University, North Chicago, Illinois</aff><aff id="aff2"><label>b</label>Albert Einstein College of Medicine, Bronx, New York</aff><aff id="aff3"><label>c</label>Frontier Dermatology, Mill Creek, Washington</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Correspondence to: Olivia Katamanin, BS, Chicago Medical School, Rosalind Franklin University, 3333 N Green Bay Rd, North Chicago, IL 60064. <email>olivia.katamanin@my.rfums.org</email></corresp><corresp id="cor2"><label>&#x02217;</label>Eingun James Song, MD, Frontier Dermatology, 15906 Mill Creek Blvd, Mill Creek, WA. <email>esong812@gmail.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>14</day><month>11</month><year>2023</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>1</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>14</day><month>11</month><year>2023</year></pub-date><volume>43</volume><fpage>36</fpage><lpage>39</lpage><permissions><copyright-statement>&#x000a9; 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>American Academy of Dermatology, Inc.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><kwd-group id="kwrds0010"><title>Key words</title><kwd>alopecia areata</kwd><kwd>baricitinib</kwd><kwd>case series</kwd><kwd>JAK inhibitors</kwd><kwd>prior JAK inhibitor failure</kwd><kwd>treatment</kwd></kwd-group></article-meta><def-list><title>Abbreviations used</title><def-item><term id="kwrd0045">AD</term><def><p>Aatopic Ddermatitis</p></def></def-item><def-item><term id="kwrd0055">AT</term><def><p>Alopecia Totalis</p></def></def-item><def-item><term id="kwrd0065">AU</term><def><p>Alopecia Universalis</p></def></def-item><def-item><term id="kwrd0075">DM2</term><def><p>Type 2 Diabetes Mellitus</p></def></def-item><def-item><term id="kwrd0085">JAK</term><def><p>Janus kinase</p></def></def-item><def-item><term id="kwrd0095">SALT</term><def><p>Severity of Alopecia Tool</p></def></def-item><def-item><term id="kwrd0105">QD</term><def><p>Quarter Daily</p></def></def-item></def-list></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Severe alopecia areata (AA), defined by hair loss &#x02265;50% of the scalp, was traditionally treated with various off-label therapies including systemic steroids, immunosuppressants, and contact sensitization.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> The Food and Drug Administration approval of baricitinib in June 2022, a selective Janus kinase (JAK) 1/2 inhibitor, marked the first on-label treatment for AA.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Before baricitinib, several case reports of oral tofacitinib, a JAK1/3 inhibitor, and oral ruxolitinib, a JAK1/2 inhibitor, demonstrated the potential to treat AA by targeting the JAK/STAT pathway.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Yet, there were still a significant number of nonresponders to these agents which poses the question of whether alternative JAK inhibitors with different selectivity may still be beneficial in these patients. Because prior JAK inhibitor use was an exclusion criteria in the BRAVE AA-1 and BRAVE AA-2 trials, there is currently limited data to support the use of baricitinib in prior JAK inhibitor failures. Herein, we report our experience in 3 patients with severe AA that have failed a prior JAK inhibitor. <xref rid="tbl1" ref-type="table">Table I</xref> details the baseline demographics and treatment outcomes for each patient. The Severity of Alopecia Tool (SALT) was used to describe the extent of scalp-hair loss in patients.<table-wrap position="float" id="tbl1"><label>Table I</label><caption><p>Demographics and treatment outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Case 1</th><th>Case 2</th><th>Case 3</th></tr></thead><tbody><tr><td>Age (y) at initial visit, sex</td><td>70/F</td><td>56/F</td><td>73/F</td></tr><tr><td>PMH</td><td>Asthma, hyperlipidemia, hypothyroidism</td><td>Hypothyroidism</td><td>Hypothyroidism, AD, hypertension, DM2</td></tr><tr><td>SALT baseline</td><td>53 (AT previously)</td><td>AU</td><td>AU</td></tr><tr><td>Duration of disease</td><td>&#x0003e;10&#x000a0;y</td><td>3</td><td>1</td></tr><tr><td>Prior Rx</td><td>Prednisone, cyclosporine, methotrexate, intralesional kenalog injections, fexofenadine, ezetimibe/simvastatin, diphenylcyclopropenone</td><td>Prednisone, methotrexate, tofacitinib, low dose oral minoxidil</td><td>Prednisone, cyclosporine, methotrexate, intralesional kenalog injections, dupilumab, low dose oral minoxidil, tofacitinib</td></tr><tr><td>Baricitinib dose (daily)</td><td>4&#x000a0;mg</td><td>4&#x000a0;mg</td><td>4&#x000a0;mg</td></tr><tr><td>SALT response</td><td>20</td><td>40</td><td>5</td></tr><tr><td>Clin-RO eyebrow/lashes</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Time off of previous JAKi before starting baricitinib</td><td>12&#x000a0;months off of upadacitinib</td><td>3 months off of tofacitinib</td><td>6 months off of upadacitinib<break/>24&#x000a0;months off of tofacitinib</td></tr><tr><td>Duration of baricitinib (mo)</td><td>6</td><td>9</td><td>8</td></tr></tbody></table><table-wrap-foot><fn><p><italic>AD</italic>, Atopic dermatitis; <italic>AT</italic>, alopecia totalis; <italic>AU</italic>, alopecia universalis; <italic>Clin-RO</italic>, clinician reported outcome; <italic>DM2</italic>, type 2 diabetes mellitus; <italic>PMH</italic>, past medical history; <italic>Rx</italic>, treatment; <italic>SALT</italic>, Severity of Alopecia Tool.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2"><title>Case 1</title><p id="p0015">A 70-year-old female presented to our dermatology clinic with a SALT baseline of 53 and disease duration of more than 10&#x000a0;years (<xref rid="fig1" ref-type="fig">Fig 1</xref>, <italic>A</italic>). Her affected areas included her frontoparietal scalp and occiput. Her past medical history was significant for asthma, hyperlipidemia, and hypothyroidism. She was previously treated with off-label upadacitinib 30&#x000a0;mg daily, a selective JAK1 inhibitor, for 6&#x000a0;months without any appreciable hair growth. Other treatments included prednisone, cyclosporine, methotrexate, intralesional kenalog injections, fexofenadine, ezetimibe/simvastatin, and diphenylcyclopropenone. She had achieved partial response to methotrexate 22.5&#x000a0;mg/week for years but was never able to achieve SALT 20. The patient was prescribed 4&#x000a0;mg of baricitinib daily for a 6&#x000a0;month duration in which she achieved SALT 20 (<xref rid="fig1" ref-type="fig">Fig 1</xref>, <italic>B</italic>).<fig id="fig1"><label>Fig 1</label><caption><p><bold>A,</bold> Pretreatment image of case 1 showing multiple areas of nonscarring alopecia after failing upadacitinib. <bold>B,</bold> Posttreatment image of case 1 showing marked improvement after 6&#x000a0;months.</p></caption><graphic xlink:href="gr1"/></fig></p></sec><sec id="sec3"><title>Case 2</title><p id="p0020">A 56-year-old female presented to our dermatology clinic with alopecia universalis with an ongoing disease duration of 3&#x000a0;years. Her past medical history was significant for hypothyroidism. She was treated with tofacitinib 11&#x000a0;mg extended-release which resulted in her eyebrows and eyelashes growing back but no scalp-hair growth after 1.5&#x000a0;years of treatment (<xref rid="fig2" ref-type="fig">Fig 2</xref>, <italic>A</italic>). Prior treatments included prednisone, methotrexate, and low dose oral minoxidil. The patient was prescribed 4&#x000a0;mg of baricitinib daily for a 9&#x000a0;month duration in which her SALT decreased to 40. While the patient&#x02019;s temporal and occipital scalp fully grew, her vertex was still bald (<xref rid="fig2" ref-type="fig">Fig 2</xref>, <italic>B</italic> and <italic>C</italic>).<fig id="fig2"><label>Fig 2</label><caption><p><bold>A,</bold> Pretreatment image of case 2 while on tofacitinib 11&#x000a0;mg extended release. <bold>B,</bold> Posttreatment image of case 2 showing slight improvement after 5&#x000a0;months of baricitinib 4&#x000a0;mg every day. <bold>C,</bold> Posttreatment image of case 2 demonstrating further improvement after 9&#x000a0;months of baricitinib 4&#x000a0;mg every day.</p></caption><graphic xlink:href="gr2"/></fig></p></sec><sec id="sec4"><title>Case 3</title><p id="p0025">A 73-year-old female presented to our dermatology clinic with alopecia universalis with an ongoing disease duration of 1&#x000a0;year. Her past medical history was significant for hypothyroidism, atopic dermatitis (AD), hypertension, and type 2 diabetes mellitus. She was previously treated with prednisone, cyclosporine, methotrexate, and intralesional kenalog injections. She actually showed near-complete hair regrowth with dupilumab but developed severe conjunctivitis which was unresponsive to various therapies from ophthalmology which prompted her to temporarily discontinue. Shortly after stopping dupilumab, the patient lost all of her hair and was never able to recapture after restarting dupilumab. Patient was then started on tofacitinib 11&#x000a0;mg extended release but did not show any appreciable hair growth at 6&#x000a0;months and was unable to continue due to loss of foundation support from the drug manufacturer. Because the patient also had concomitant moderate-to-severe AD, she was started on upadacitinib 15&#x000a0;mg daily with up titration to 30&#x000a0;mg at 3&#x000a0;months. While her AD completely cleared, she achieved just partial hair regrowth after 6&#x000a0;months of therapy and subsequently relapsed to a SALT 100 (<xref rid="fig3" ref-type="fig">Fig 3</xref>, <italic>A</italic>). Patient was subsequently started on baricitinib 4&#x000a0;mg daily and by 8&#x000a0;months had achieved SALT 5 (<xref rid="fig3" ref-type="fig">Fig 3</xref>, <italic>B</italic>). However, her AD has worsened and is being managed with topical corticosteroids.<fig id="fig3"><label>Fig 3</label><caption><p><bold>A,</bold> Pretreatment image of case 3 after failing upadacitinib. <bold>B,</bold> Posttreatment image of case 3 showing marked improvement after 8&#x000a0;months of baricitinib 4&#x000a0;mg every day.</p></caption><graphic xlink:href="gr3"/></fig></p></sec><sec id="sec5"><title>Discussion</title><p id="p0030">Significant advancements have been made in the treatment of severe AA since June 2022, with now 2 Food and Drug Administration-approved medications in baricitinib, a JAK1/2 inhibitor, and ritlecitinib, a JAK3/TEC inhibitor. Both treatments have demonstrated the potential for near-complete hair growth in a significant number of patients with an acceptable safety profile.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Still, &#x0003e;60% of patients still did not reach the primary end point of SALT 20 with both medications, demonstrating the need for additional therapies. While it can be useful to think about medications in a certain class together, differences in JAK selectivity can confer efficacy and safety advantages.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> In both rheumatoid arthritis and psoriatic arthritis where JAK inhibitors are also Food and Drug Administration-approved treatments, it has been shown that certain patients who failed a prior JAK inhibitor can benefit from switching to another JAK inhibitor.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> Likewise, we have shown in a small number of patients that prior JAK inhibitor failure should not preclude the use of baricitinib.</p><p id="p0035">Pharmacologic inhibitory differences of the various JAK isoforms may lead to greater inhibition of relevant AA cytokines, namely interleukin-15 and interferon-gamma, and may explain differences in clinical efficacy. As first generation JAK inhibitors, tofacitinib and baricitinib will inhibit a broader range of cytokines than upadacitinib which may be advantageous in a heterogenous disease such as AA.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> Furthermore, because JAK inhibition and selectivity is dose-dependent, it is possible that using a higher dose of tofacitinib and upadacitinib would have yielded better results. In addition, differences in drug half-life, tissue penetration and distribution, individual variations in single nucleotide polymorphisms affecting STAT isoforms, and differential expression of JAK expression at sites of inflammation may explain differences in treatment response with a particular JAK inhibitor.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref></p><p id="p0040">Our case series also brings to the light the importance of considering comorbidities. While baricitinib is approved in Japan and European Union for moderate-to-severe AD, the efficacy was considerably lower than what was seen in the pivotal trials.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> Not unsurprisingly, patient 3 had a flare in her AD after switching to baricitinib.</p><p id="p0045">The limitations of this case series include a small sample size and a fairly short follow-up period. Although all 3 patients started with the 4&#x000a0;mg dose of baricitinib, it is unclear if the 2&#x000a0;mg dose would have been sufficient. Future research on identifying patient characteristics that may identify a more favorable response to a particular JAK inhibitor is needed.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest</title><p id="p0050">None disclosed.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L.Y.</given-names></name><name><surname>King</surname><given-names>B.A.</given-names></name></person-group><article-title>Ruxolitinib for the treatment of severe alopecia areata</article-title><source>J Am Acad Dermatol</source><volume>80</volume><issue>2</issue><year>2019</year><fpage>566</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2018.08.040</pub-id><pub-id pub-id-type="pmid">30195572</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>O.</given-names></name><name><surname>Senna</surname><given-names>M.M.</given-names></name><name><surname>Sinclair</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2)</article-title><source>Am J Clin Dermatol</source><volume>24</volume><issue>3</issue><year>2023</year><fpage>443</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1007/s40257-023-00764-w</pub-id><pub-id pub-id-type="pmid">36855020</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L.Y.</given-names></name><name><surname>Craiglow</surname><given-names>B.G.</given-names></name><name><surname>Dai</surname><given-names>F.</given-names></name><name><surname>King</surname><given-names>B.A.</given-names></name></person-group><article-title>Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients</article-title><source>J Am Acad Dermatol</source><volume>76</volume><issue>1</issue><year>2017</year><fpage>22</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2016.09.007</pub-id><pub-id pub-id-type="pmid">27816293</pub-id>
</element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>King</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Harcha</surname><given-names>W.G.</given-names></name><etal/></person-group><article-title>A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata</article-title><source>Immunotherapy</source><volume>15</volume><issue>14</issue><year>2023</year><fpage>1093</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.2217/imt-2023-0069</pub-id><pub-id pub-id-type="pmid">37403610</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Hordinsky</surname><given-names>M.</given-names></name><name><surname>Hebert</surname><given-names>A.A.</given-names></name><name><surname>Gooderham</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Efficacy and safety of ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial</article-title><source>Pediatr Dermatol</source><year>2023</year><pub-id pub-id-type="doi">10.1111/pde.15378</pub-id><comment>Online ahead of print</comment></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>B.</given-names></name><name><surname>Song</surname><given-names>X.</given-names></name></person-group><article-title>Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis</article-title><source>Front Immunol</source><volume>14</volume><year>2023</year><object-id pub-id-type="publisher-id">1152513</object-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1152513</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Amstad</surname><given-names>A.</given-names></name><name><surname>Papagiannoulis</surname><given-names>E.</given-names></name><name><surname>Scherer</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy</article-title><source>Rheumatology (Oxford)</source><volume>62</volume><issue>1</issue><year>2022</year><fpage>89</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/keac285</pub-id><pub-id pub-id-type="pmid">35579338</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Shawky</surname><given-names>A.M.</given-names></name><name><surname>Almalki</surname><given-names>F.A.</given-names></name><name><surname>Abdalla</surname><given-names>A.N.</given-names></name><name><surname>Abdelazeem</surname><given-names>A.H.</given-names></name><name><surname>Gouda</surname><given-names>A.M.</given-names></name></person-group><article-title>A comprehensive overview of globally approved JAK inhibitors</article-title><source>Pharmaceutics</source><volume>14</volume><issue>5</issue><year>2022</year><fpage>1001</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics14051001</pub-id><pub-id pub-id-type="pmid">35631587</pub-id>
</element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>O&#x02019;Shea</surname><given-names>J.J.</given-names></name><name><surname>Nakayamada</surname><given-names>S.</given-names></name></person-group><article-title>Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach</article-title><source>Nat Rev Rheumatol</source><volume>18</volume><issue>3</issue><year>2022</year><fpage>133</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1038/s41584-021-00726-8</pub-id><pub-id pub-id-type="pmid">34987201</pub-id>
</element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>H.</given-names></name><name><surname>Jia</surname><given-names>H.</given-names></name><name><surname>Xia</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name></person-group><article-title>Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis</article-title><source>Dermatol Ther</source><volume>35</volume><issue>9</issue><year>2022</year><object-id pub-id-type="publisher-id">e15636</object-id><pub-id pub-id-type="doi">10.1111/dth.15636</pub-id></element-citation></ref></ref-list><fn-group><fn id="d35e172"><p id="ntpara0010">Funding sources: None.</p></fn><fn id="d35e175"><p id="ntpara0015">Patient consent: The authors obtained written consent from patients for their photographs and medical information to be published in print and online and with the understanding that this information may be publicly available. Patient consent forms were not provided to the journal but are retained by the authors.</p></fn><fn id="d35e178"><p id="ntpara0020">IRB approval status: Not applicable.</p></fn></fn-group></back></article>
